Business Description
Denali Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US24823R1059
Description
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 18.54 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.25 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 11.97 | |||||
| Beneish M-Score | 13.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -6.9 | |||||
| 3-Year Book Growth Rate | -7.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.44 | |||||
| 9-Day RSI | 66.16 | |||||
| 14-Day RSI | 58.92 | |||||
| 6-1 Month Momentum % | 11.35 | |||||
| 12-1 Month Momentum % | -28.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.79 | |||||
| Quick Ratio | 11.79 | |||||
| Cash Ratio | 11.34 | |||||
| Days Sales Outstanding | 7.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.7 | |||||
| Shareholder Yield % | -18.85 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -70.46 | |||||
| Net Margin % | -46.46 | |||||
| FCF Margin % | -144.02 | |||||
| ROE % | -11.92 | |||||
| ROA % | -10.26 | |||||
| ROIC % | -76.6 | |||||
| ROC (Joel Greenblatt) % | -292.27 | |||||
| ROCE % | -17.36 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.74 | |||||
| PB Ratio | 1.79 | |||||
| Price-to-Tangible-Book | 1.79 | |||||
| EV-to-EBIT | -8.29 | |||||
| EV-to-Forward-EBIT | -5.09 | |||||
| EV-to-EBITDA | -8.65 | |||||
| EV-to-Forward-EBITDA | -5.2 | |||||
| EV-to-Revenue | 5.84 | |||||
| EV-to-Forward-Revenue | 21.43 | |||||
| EV-to-FCF | -4.06 | |||||
| Price-to-Projected-FCF | 20.96 | |||||
| Price-to-Net-Current-Asset-Value | 3.08 | |||||
| Price-to-Net-Cash | 3.22 | |||||
| Earnings Yield (Greenblatt) % | -12.06 | |||||
| FCF Yield % | -16.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Denali Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 272.663 | ||
| EPS (TTM) (€) | -0.89 | ||
| Beta | 0.36 | ||
| Volatility % | 58.47 | ||
| 14-Day RSI | 58.92 | ||
| 14-Day ATR (€) | 0.557926 | ||
| 20-Day SMA (€) | 15.50575 | ||
| 12-1 Month Momentum % | -28.04 | ||
| 52-Week Range (€) | 13.79 - 30.32 | ||
| Shares Outstanding (Mil) | 142.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Denali Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Denali Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Denali Therapeutics Inc Frequently Asked Questions
What is Denali Therapeutics Inc(STU:4DN)'s stock price today?
The current price of STU:4DN is €17.19. The 52 week high of STU:4DN is €30.32 and 52 week low is €13.79.
When is next earnings date of Denali Therapeutics Inc(STU:4DN)?
The next earnings date of Denali Therapeutics Inc(STU:4DN) is 2024-08-08 Est..
Does Denali Therapeutics Inc(STU:4DN) pay dividends? If so, how much?
Denali Therapeutics Inc(STU:4DN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers